Key result
HIPA+/PIPA+ status is linked to ~47% higher thrombosis prevalence compared to negative functional assays.
Why the study?
Information on heparin-independent anti-PF4 antibodies in larger populations remains limited, despite well-described data on heparin-dependent HIT antibodies.
Cohort (n=474)
Absolute Event Rate: 47.7% vs 32.5%
p-value: p=.016
Combined HIPA and PIPA testing identifies functional antibody phenotypes associated with increasing thrombotic risk, suggesting PF4-dependent antibodies are more frequent than previously anticipated.
No takes yet. Share an insight, caveat, or question.
May support combined HIPA/PIPA testing for thrombotic risk stratification in suspected HIT; leaves open need for prospective validation.
Scheuer et al. (2026) conducted a cohort in Suspected heparin-induced thrombocytopenia (HIT) or other anti-PF4 disorders (n=474). PF4-dependent and heparin-dependent platelet-activating antibodies vs. Negative results in both functional assays was evaluated on Thrombosis (p=.016). Thrombosis prevalence increased stepwise from 32.5% in patients with negative functional assays to 40.0% in HIPA+/PIPA- patients and 47.7% in HIPA+/PIPA+ patients (P for trend = .016).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: